News Breaks |
|
|
| March 18, 2013 |
| 13:01 EDT |  | XOMA | XOMA names Tom Klein as Chief Commercial Officer
XOMA announced Tom Klein has joined the company as Chief Commercial Officer, a newly created position reporting to John Varian, XOMA's CEO. Klein brings over 25 years of successful brand commercialization leadership, with an expertise in commercializing biologic products to medical specialists. Klein joins XOMA from Genentech, where he was Vice President, Business Unit Head Virology and Specialty Care. |
|
|
News For XOMA From The Last 14 Days Check below for free stories on XOMA the last two weeks. |
|
|
| May 20, 2013 |
| 10:16 EDT |  | XOMA | XOMA management to meet with Roth Capital
 Subscribe for More Information |
|
| May 10, 2013 |
| 07:24 EDT | | XOMA | Credit Suisse to host a conference
Subscribe for More Information |
|
| May 9, 2013 |
| 14:00 EDT |  | XOMA | XOMA price target raised to $6 from $5 at Ladenburg
Ladenburg raised its price target on XOMA after the company reported top-line Phase II data for its Behcet's Uveitis treatment, Gevokizumab, that the firm views as positive. Ladenbirg thinks the data further derisks the upcoming EYEGUARD-A trial and it reiterates a Buy rating on XOMA. |
|
| 10:08 EDT |  | XOMA | On The Fly: Analyst Upgrade Summary
Subscribe for More Information |
|
| 07:29 EDT | | XOMA | XOMA upgraded to Buy from Hold at Canaccord
Subscribe for More Information |
|
| May 8, 2013 |
| 16:11 EDT |  | XOMA | XOMA reports Q1 EPS (30c), consensus (20c)
Subscribe for More Information |
|
|
|
|
|
